Corona Remedies IPO Lists at 38% Premium, Investors See Huge Gains

• Corona Remedies IPO listed at a 38% premium, opening at ₹1,470 on NSE and ₹1,452 on BSE against an issue price of ₹1,062.
• The IPO was oversubscribed 137.04 times, indicating strong investor interest.
• Institutional buyers (QIB) subscribed 278.52 times, non-institutional investors (NII) 208.88 times, and retail investors 28.73 times.
• The company specializes in medicines for women's health, cardio-diabetes, and other chronic diseases.

Why It Matters: This IPO's strong listing means big profits for investors.